

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jinxin Fertility Group Limited**

**錦欣生殖醫療集團有限公司\***

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 1951)**

## **CHANGE OF NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES**

### **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Jinxin Fertility Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that effective from the date of this announcement, Mr. Fang Min has resigned as non-executive Director and member of each of the audit and risk management committee (“**Audit and Risk Management Committee**”), remuneration committee (“**Remuneration Committee**”) and strategic decisions committee (“**Strategic Decisions Committee**”) of the Board so as to devote more time to his other business commitments. Mr. Fang has confirmed that he has no disagreement with the Board, and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

### **APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that Mr. Shuyun Chen (陳樹云) (also known as Nick Chen) (“**Mr. Chen**”) has been appointed as non-executive Director with effect from the date of this announcement.

The biographical details of Mr. Chen are as follows:

Mr. Chen, aged 50, spent over 18 years with the Capital Group Companies (“**Capital Group**”), one of the world’s largest and most successful professional investment organizations. In 2024, he retired from Capital Group as Partner in charge of Capital Group Private Markets (“**CGPM**”) in the Greater China region and a member of CGPM’s global Portfolio Management Committee. During his tenure, he successfully invested in, advised, and served as a board director of many leading companies in the healthcare, technology, and financial industries. Prior to joining Capital Group in 2005, Mr. Chen worked at J.P. Morgan in investment banking roles in New York and Hong Kong from 1999, leaving as Vice President of the Asia mergers and acquisitions group. He is currently a member of the board of managers of HRC Fertility Management, LLC. and a member of the board of PT Morula Indonesia. Mr. Chen obtained his Bachelor of Arts degree (summa cum laude) in Business and Economics from Franklin & Marshall College in the United States in May 1997.

Mr. Chen was a non-executive Director of Innovent Biologics Inc. (a company listed on the Stock Exchange with stock code: 1801) between January 2018 and February 2022, and has served as the lead independent non-executive director since May 2024. Mr. Chen has also served as an independent director of Shanghai Yaohua Pilkington Glass Group Co., Ltd. (a company listed on the Shanghai Stock Exchange with stock code: 600819) since June 2024. Save as disclosed above, he does not hold any other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Mr. Chen has entered into a letter of appointment with the Company for a term of three years which is terminable by either party with one month’s written notice, and shall hold office until the next general meeting of the Company, and be eligible for re-election at such annual general meeting pursuant to the articles of association of the Company. He will not receive any director’s fee for his appointment as a non-executive Director, and he does not have any relationship with any Directors, senior management or substantial Shareholders.

As at the date of this announcement, save as disclosed above, (i) Mr. Chen is not interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) he does not hold any other position in the Company or members of the Group; (iii) he does not possess any other professional qualifications; and (vi) there is no other information that need to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and there are no other matters that need to be brought to the attention of the Shareholders in relation to his appointment.

## **CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board further announces that Mr. Chen has also been appointed as a member of each of the Audit and Risk Management Committee, Remuneration Committee and Strategic Decisions Committee with effect from the date of this announcement.

The Board would like to express its sincere gratitude to Mr. Fang for his valuable contribution to the Company during his tenure of service, and extend its warmest welcome to Mr. Chen on his new appointment.

By order of the Board  
**Jinxin Fertility Group Limited**  
**Dong Yang**  
*Chief Executive Officer, Acting Chief  
Financial Officer and Executive Director*

Hong Kong, September 25, 2025

*As at the date of this announcement, the Board comprises Mr. Dong Yang, Ms. Lyu Rong and Dr. Geng Lihong, as executive Directors; Mr. Zhong Yong, as Chairman and non-executive Director, Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive Directors; and Dr. Chong Yat Keung, Mr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.*

\* *For identification purposes only*